Your browser doesn't support javascript.
loading
Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.
Bernasconi, Camilla; Pelkonen, Olavi; Andersson, Tommy B; Strickland, Judy; Wilk-Zasadna, Iwona; Asturiol, David; Cole, Thomas; Liska, Roman; Worth, Andrew; Müller-Vieira, Ursula; Richert, Lysiane; Chesne, Christophe; Coecke, Sandra.
Afiliação
  • Bernasconi C; European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Pelkonen O; Research Unit of Biomedicine/Pharmacology and Toxicology, Faculty of Medicine, Aapistie 5B, University of Oulu, FIN-90014, Finland; Clinical Research Center, Oulu University Hospital, Finland.
  • Andersson TB; Drug Metabolism and Pharmacokinetics, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Strickland J; Integrated Laboratory Systems (contractor supporting NICEATM), Research Triangle Park, North, Carolina, 27709, USA.
  • Wilk-Zasadna I; European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Asturiol D; European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Cole T; European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Liska R; European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Worth A; European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Müller-Vieira U; Boehringer Ingelheim, Germany. Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, an der Riss, Germany.
  • Richert L; KaLy-Cell, 20A, rue du Général Leclerc, 67115 Plobsheim, France(g) Biopredic International, Parc d'activité de la Bretèche Bâtiment A4, 35760 Saint Grégoire, France.
  • Chesne C; Biopredic International, Parc d'activité de la Bretèche Bâtiment A4, 35760 Saint Grégoire, France.
  • Coecke S; European Commission, Joint Research Centre (JRC), Ispra, Italy. Electronic address: sandra.coecke@ec.europa.eu.
Toxicol In Vitro ; 60: 212-228, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31158489
ABSTRACT
CYP enzyme induction is a sensitive biomarker for phenotypic metabolic competence of in vitro test systems; it is a key event associated with thyroid disruption, and a biomarker for toxicologically relevant nuclear receptor-mediated pathways. This paper summarises the results of a multi-laboratory validation study of two in vitro methods that assess the potential of chemicals to induce cytochrome P450 (CYP) enzyme activity, in particular CYP1A2, CYP2B6, and CYP3A4. The methods are based on the use of cryopreserved primary human hepatocytes (PHH) and human HepaRG cells. The validation study was coordinated by the European Union Reference Laboratory for Alternatives to Animal Testing of the European Commission's Joint Research Centre and involved a ring trial among six laboratories. The reproducibility was assessed within and between laboratories using a validation set of 13 selected chemicals (known human inducers and non-inducers) tested under blind conditions. The ability of the two methods to predict human CYP induction potential was assessed. Chemical space analysis confirmed that the selected chemicals are broadly representative of a diverse range of chemicals. The two methods were found to be reliable and relevant in vitro tools for the assessment of human CYP induction, with the HepaRG method being better suited for routine testing. Recommendations for the practical application of the two methods are proposed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema Enzimático do Citocromo P-450 / Indutores das Enzimas do Citocromo P-450 Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema Enzimático do Citocromo P-450 / Indutores das Enzimas do Citocromo P-450 Idioma: En Ano de publicação: 2019 Tipo de documento: Article